74 / 74
CARZIN XL.
Each tablet contains 4 mg doxazosin. S3 A41/7.1/0557. NAM NS2 10/34/0376. For full prescribing information, refer to the professional information approved by SAHPRA, 12 June 2015.
1)
Pompeo ACL,
et al.
A
randomised, double blind study comparing the efficacy and tolerability of controlled release Doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia. Int J. Clin Pract Oct 2006;60(10):1172-1177.
2)
Kirby RS,
et
al.
A Combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. British Journal of Urology
International 2001 Feb;87(3):192-200.
3)
Approved professional information.
4)
Database of Medicine Prices (13 April 2018). Department of Health website.
http://www.mpr.gov.za- Accessed on 13 April 2018.
CXLE469/04/2018.
DOXAZOSIN 4 mg
onset for
consistent flow
1
Slower
A
slower
onset of action vs IR formulations to allow
fewer titration steps and to minimize side-e ects
2
.
E ective
treatment for urinary outflow obstruction
and BPH symptoms
3
.
Safe
BPH treatment for normotensive and
hypertensive patients
3
.
Carzin XL
, the extended release doxazosin o ers:
A Lupin Group Company
COST SAVING
vs THE ORIGINATOR
4
%
53
MORE THAN
For further product information contact
PHARMA DYNAMICS
P O Box 30958 Tokai Cape Town 7966
Fax
+27 21 701 5898
CUSTOMER CARE LINE
0860 PHARMA (742 762) / +27 21 707 7000
www.pharmadynamics.co.za